文献速递眼底病与葡萄膜炎

新生血管性年龄相关性黄斑变性患者玻璃体内注射阿柏西普的药代动力学研究

PHARMACOKINETIC STUDY OF INTRAVITREAL AFLIBERCEPT IN HUMANS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
PubMed 文献 · Retina · 2020-01-01

这项前瞻性、非对照、干预性病例系列纳入5只未接受过抗血管内皮生长因子治疗的新生血管性年龄相关性黄斑变性眼,单次玻璃体内注射阿柏西普后于4小时及第1、3、7、14、28天采集房水与血液/血浆。房水中游离阿柏西普中位峰值浓度为122 mg/L,中位半衰期为11天;血浆中游离阿柏西普浓度低且短暂,注射后第一周内即降至检测不到,第7天之后所有患者均检测不到。

要点

  • 房水中游离阿柏西普中位峰值浓度为122 mg/L,中位半衰期为11天。
  • 血浆中游离阿柏西普浓度低且短暂,注射后第一周内降至检测不到。
  • 第7天之后所有患者血浆中游离阿柏西普均检测不到。

核心结论

  • 房水中药代动力学特征与阿柏西普对血管内皮生长因子的已知亲和力一致,并加深了对其临床疗效持续时间的理解。

研究设计与样本

  • 前瞻性、非对照、干预性病例系列,纳入5只未接受过抗血管内皮生长因子治疗的新生血管性年龄相关性黄斑变性眼,单次玻璃体内注射阿柏西普。
  • 基线及治疗后4小时和第1、3、7、14、28天共6个时间点采集房水与血液/血浆,用酶联免疫吸附试验定量阿柏西普浓度。

主要发现

  • 房水中游离阿柏西普中位峰值浓度为122 mg/L。
  • 房水中游离阿柏西普中位半衰期为11天。
  • 血浆中游离阿柏西普浓度低且短暂,注射后第一周内降至检测不到,第7天之后所有患者均检测不到。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the half-life of aflibercept in aqueous humor after a single intravitreal injection in patients with neovascular age-related macular degeneration. METHODS: Prospective, noncomparative, interventional case series of five eyes with neovascular age-related macular degeneration naive to anti-vascular endothelial growth factor therapy were enrolled and treated with intravitreal aflibercept. At baseline, best-corrected visual acuity, optical coherence tomography imaging, and aqueous humor (treatment eye) and blood/plasma samples were taken. Patients underwent best-corrected visual acuity, optical coherence tomography imaging, and sampling of aqueous humor from the eye and blood/plasma at six additional post-treatment time points of 4 hours and Days 1, 3, 7, 14, and 28. Concentrations of aflibercept were quantified using an enzyme-linked immunosorbent assay. RESULTS: Median peak concentration (Cmax) of free aflibercept in the aqueous was 122 mg/L. The median half-life of free aflibercept was 11 days in the eye. In plasma, the concentrations of free aflibercept were low and transient, reaching undetectable levels during the first week after injection, and undetectable in all patients at time points beyond 7 days. CONCLUSION: The pharmacokinetic profile in the aqueous humor described here together with the previously reported affinity of aflibercept for vascular endothelial growth factor is consistent with and adds to our understanding for the duration of its clinical efficacy.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Do DV, Rhoades W, Nguyen QD, et al. PHARMACOKINETIC STUDY OF INTRAVITREAL AFLIBERCEPT IN HUMANS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 2020. PMID: 31145389. doi:10.1097/IAE.0000000000002566

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。